Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of PEG-rhGH Preparations in Healthy Adults
NCT06331026Phase 1Completed
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Apr 2024
- Primary completion
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of peg-somatropin in growth hormone deficiency (GHD) (3 arms), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoints: Peak Plasma Concentration, Area under the concentration-time curve from time zero to time infinity and 1 more. Started Apr 2024; status: completed.
02
Drugs
peg-somatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT06331026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06331026.